"So that’s all well and good, but why the upside at of the magnitude seen in the trial? Well, the positive data has implicationsbeyond an advancing of MIN-101 into a pivotal trial. Specifically, it paves the way for a potential partensrhip between Minerva and big pharma – a partnership that would not only secure the funding for the drug going forward (i.e. between now and commercialization) but also provide some near term development capital for Minerva, and – longer term – potential royalties on the back of a big pharma backed sales drive for the products in question."
News 
Market Data 
Discover 
